Pricing Log in Create free account
Saturday 17 October 2026 Export SNGX’s income statement to Excel — free account

Soligenix Inc.

SNGX Healthcare Biotechnology

Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.

0.35 0.01 −2.78%
Market cap
$7.7M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−38.90
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 7.73
Revenue 0.49
Net Income (10.24)
Free Cash Flow (9.74)
Net Debt (9.81)
Current Ratio 2.77 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.53) (negative: loss-making)
P/S ratio 11.29 (above 10: high)
P/B ratio 0.84
Past 5Y EPS Growth —
This Y EPS Growth 81.31% (at or above 15%: strong)
Next Y EPS Growth 37.50% (at or above 15%: strong)
Next Y revenue growth 318.76% (at or above 10%: strong)
Next 5Y EPS Growth 48.16% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −3.7×, against a ten-year median of 1.7×; over the ten years it ranged from −7.1× in 2023 to 31.4× in 2022.
P/S against its own 10 years 60.27%
10-year low 10-year high
P/B against its own 10 years 3.85%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 8 8 8 10
Receivables 0 — — —
Inventory — — — —
Other — 0 0 0
10 9 9 10
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt 2 1 — —
Other — — — —
6 5 4 4

Compound Annual Growth %

10y 5y 3y
Sales (33.48%) (51.88%) (47.48%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 7.18% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 0 0 — — 0
’23 0 0 0 0 1
’22 0 0 0 0 1
’21 0 0 0 0 1
’20 1 1 1 0 2
’19 1 2 1 1 5
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (2) (3) (3) (3) (10)
’24 (1) (2) (3) (2) (8)
’23 (2) (2) (3) (2) (9)
’22 (3) (3) (3) (4) (13)
’21 (4) (2) (3) (3) (12)
’20 (3) (2) (3) (4) (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (2) (3) (3) (3) (10)
’24 (1) (2) (3) (2) (8)
’23 (2) (2) (3) (2) (9)
’22 (3) (3) (3) (4) (13)
’21 (4) (2) (3) (3) (12)
’20 (3) (2) (3) (4) (11)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.28) (0.12) — — —
’25 (1.06) (0.82) (0.58) 0.24 (2.14)
’24 (2.88) (1.31) (0.78) (1.14) (4.98)
’23 (5.76) (3.52) (2.56) (2.56) (12.64)
’22 (23.99) (14.39) (19.19) (20.82) (76.96)
’21 (14.39) (11.99) (21.59) (26.39) (74.36)
’20 (76.76) (23.99) (14.39) (45.58) (153.52)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 492.00 417.60 192.00 156.00 290.40 158.40 91.20 6.08 1.83 1.09

Analyst estimates 2026–2028

Powerpack
High 3,000.00 1,219.20 888.00 357.60 849.60 595.20 240.00 129.60 19.20 6.23
People
People Employees 19 18 14 16 18 15 15 15 16 14
Revenue/emp, $m 0.55 0.30 0.37 0.29 0.13 0.05 0.06 0.06 0.01 0.00
Income, $m
Income, $m Revenue 10 5 5 5 2 1 1 1 0 —
Gross margin, % 19.29 20.66 12.28 22.95 22.82 11.60 41.95 11.59 0.00 —
EBT (4) (8) (9) (10) (19) (13) (15) (8) (9) (12)
EBT margin, % (36.13) (139.23) (169.80) (215.26) (785.17) (1,627.53) (1,575.86) (942.16) (7,266.08) 0.00
Net income (3) (7) (9) (9) (18) (13) (14) (6) (8) (11)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 720.61 212.21 95.47 57.30 20.59 4.93 5.29 1.73 0.07 0.00
Earnings (223.09) (246.96) (163.12) (115.14) (153.52) (74.36) (76.96) (12.64) (4.98) (2.14)
Cash flow (343.61) (254.32) (131.96) (92.94) (99.95) (70.21) (70.51) (17.74) (5.06) (1.98)
Capex (0.50) (1.03) (0.02) (0.31) (0.06) (0.07) (0.07) 0.00 0.00 0.00
Free cash flow (344.11) (255.35) (131.98) (93.25) (100.01) (70.28) (70.58) (17.74) (5.06) (1.98)
Book value 510.15 246.86 114.39 18.03 32.65 64.13 (13.77) 5.20 2.48 1.02
Shares, m 0 0 0 0 0 0 0 0 2 5
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
P/S 0.79 2.53 2.16 6.07 14.92 32.13 21.78 7.86 9.06 —
P/B 1.12 2.18 1.80 19.30 9.41 2.47 0.00 2.62 1.09 —
EV/Sales (0.05) 1.10 0.45 4.93 11.36 12.62 18.38 1.68 (1.93) —
EV/FCF 0.11 (0.91) (0.32) (3.03) (2.34) (0.89) (1.38) (0.16) 0.11 —
Cash, $m
Cash, $m Operating cash flow (5) (7) (7) (8) (11) (12) (13) (9) (8) (10)
Capex 0 0 0 0 0 0 0 — — 0
Free cash flow (5) (7) (7) (8) (11) (12) (13) (9) (8) (10)
Balance, $m
Balance, $m Working capital 7 6 6 1 13 20 (3) 3 4 5
Total debt — — — 0 10 10 10 3 1 —
Net debt (9) (8) (9) (5) (8) (16) (3) (5) (6) (8)
Shareholders’ equity 7 6 6 1 4 11 (2) 3 4 5
Returns, %
Returns, % ROA (36.77) (72.13) (88.82) (102.43) (127.87) (53.68) (67.06) (51.01) (88.11) (121.75)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (87.96) (104.21) (141.27) (241.83) (680.47) (173.54) (334.43) (23,801.16) (248.98) (235.50)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024

Charts ten years each

Soligenix Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR $8.1M — (loss-making) — — n/m −510.28% (below 0%: shrinking) 0.00% 0.00% Compare
XTLB XTL Biopharmaceuticals Ltd. $8.1M — (loss-making) — −39.32% (below 0%: shrinking) n/m +46.78% (above 0%: growing) 0.00% 0.00% Compare
KPTI Karyopharm Therapeutics Inc. $8.0M — (loss-making) — (loss-making) −11.86% (below 0%: shrinking) n/m −33.34% (below 0%: shrinking) 96.75% (67.38%) Compare
CNSP CNS Pharmaceuticals, Inc. $7.9M — (loss-making) — — n/m +33.70% (above 0%: growing) 0.00% 0.00% Compare
APRE Aprea Therapeutics, Inc. $7.8M — (loss-making) — (loss-making) −98.40% (below 0%: shrinking) n/m −5.22% (below 0%: shrinking) 100.00% 0.00% Compare
SNGX Soligenix Inc. $7.7M — (loss-making) — (loss-making) −98.89% (below 0%: shrinking) n/m +37.83% (above 0%: growing) 0.00% 0.00%
CURX Curanex Pharmaceuticals Inc $7.6M — (loss-making) — — n/m −272.32% (below 0%: shrinking) — 0.00% Compare
MBRX Moleculin Biotech, Inc. $7.6M 0.0× — — n/m −19.26% (below 0%: shrinking) 0.00% 0.00% Compare
CALC CalciMedica Inc. $7.4M — (loss-making) — — n/m +31.42% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $7.8M — — −39.32% — −12.24% 0.00% 0.00%

All 614 Biotechnology stocks →

Soligenix Inc. (SNGX) key facts

  • Concern: Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023.
  • Soligenix Inc. (SNGX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SNGX traded at $0.35, a market capitalization of $7.7 million.
  • Return on equity was −235.5% and debt-to-equity 0.00.
  • Its Altman Z-score is −38.90 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.

Soligenix Inc. (SNGX) Latest News

29 Apr

Impact 5 ·

28 Apr

Impact 5 ·
stockrow.com/SNGX · Data as of Jun 30, 2024 · For information only; not investment advice. · © 2026 stockrow.com